Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Total Non-current Liabilities
All obligations due after more than one year.
Biohaven Ltd.NYSE: BHVN
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities broadly unchanged from a year ago
Total non-current liabilities stood at $295.86M at the end of Q2 FY2026, up 1.5% from a year earlier and up 3.9% from the prior quarter. Over 3 fiscal years it compounded at +104.8% a year.
Context
- Total non-current liabilities amounted to 79.8% of total assets at the end of Q2 FY2026, up 26.8 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +1.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 283.44M USD
- Year-over-year change
- +657.0%
- 4-year CAGR
- +168.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 283.44M | +657.0% |
| FY2024 | 2024-12-31 | 37.45M | +25.6% |
| FY2023 | 2023-12-31 | 29.81M | -9.6% |
| FY2022 | 2022-12-31 | 32.99M | +507.0% |
| FY2021 | 2021-12-31 | 5.44M | — |
Total Non-current Liabilities vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1.5% is the 6th highest of 11, against a peer median of +1.1%.
- Total non-current liabilities amounts to 79.8% of total assets for BHVN, versus a peer median of 11.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $438.31M USD | -12.4% | +71.6% | 40.9% | |
| Sep 2026 | $366.89M USD | +13.5% | +19.8% | 24.5% | |
| Mar 2026 | $350.69M USD | +110528.4% | -31.1% | 46.9% | |
| Jun 2026 | $295.86M USD | +1.5% | +104.8% | 79.8% | |
| Mar 2026 | $260.41M USD | +1.9% | +4.9% | 66.4% | |
| Jun 2026 | $76.91M USD | +0.3% | +38.4% | 14.4% | |
| Mar 2026 | $61.4M USD | -34.4% | -24.9% | 8.1% | |
| Sep 2026 | $11.55M USD | +219.7% | -15.2% | 1.6% | |
| Sep 2026 | $10.26M USD | +155.6% | +296.2% | 2.0% | |
| Mar 2026 | $7.06M USD | -15.8% | -63.2% | 2.3% | |
| Sep 2026 | €430.28K EUR | -2.4% | +32.2% | 0.1% | |
| Peer median (excluding BHVN) | — | +1.1% | +12.3% | 11.3% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76.06M | 204.88M | 248.4M | 99.13M | 229.96M |
| Short-term Investments | 0 | 260.46M | 133.42M | 386.86M | 89.18M |
| Net Receivables | 0 | 46.14M | 13.25M | 2.6M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 12.03M | 54.54M | 12.13M | 508K | 2.17M |
| Total Current Assets | 94.82M | 586.97M | 442.45M | 538.47M | 368.33M |
| Property, Plant & Equipment (Net) | 17.68M | 52.44M | 48.58M | 53.71M | 15.96M |
| Goodwill | 1.39M | 1.39M | 1.39M | 1.39M | 1.39M |
| Intangible Assets | 18.95M | 18.4M | 18.4M | 18.4M | 18.4M |
| Long-term Investments | 6M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.22M | 2.59M | 2.4M | 3.13M | 47.36M |
| Total Non-current Assets | 47.24M | 74.82M | 70.77M | 76.64M | 83.12M |
| Total Assets | 142.06M | 661.78M | 513.21M | 615.11M | 451.45M |
| Account Payables | 4.78M | 10.7M | 15.58M | 18.03M | 11.64M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.54M | 14.6M | 35.7M | 84.71M | 59.49M |
| Total Current Liabilities | 41.94M | 90.02M | 55.42M | 154.23M | 115.93M |
| Long-term Debt | 0 | 0 | 0 | 0 | 238.9M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.64M | 2.41M | 2.25M | 4.66M | 4.58M |
| Total Non-current Liabilities | 5.44M | 32.99M | 29.81M | 37.45M | 283.44M |
| Total Liabilities | 47.37M | 123.01M | 85.24M | 191.67M | 399.38M |
| Common Stock | 34.69M | 615.74M | 887.53M | 1.66B | 1.93B |
| Retained Earnings | 0 | (91.12M) | (499.29M) | (1.35B) | (2.08B) |
| Accumulated OCI | 0 | 284K | (65K) | 79K | 8.35M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 60M | 0 | 0 | 0 | 0 |
| Total Equity | 94.69M | 538.77M | 427.98M | 423.44M | 52.07M |
| Total Debt | 3.24M | 33.6M | 30.88M | 36.58M | 284.61M |
| Net Debt | (72.82M) | (171.28M) | (217.53M) | (62.55M) | 54.66M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.